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Androgen deprivation therapy (ADT) remains the standard therapy for patients with oligome-
tastatic prostate cancer (OMPC). Prostate-specific membrane antigen positron emission
tomography/computed tomography (PSMA-PET/CT)-based stereotactic body radiotherapy
(SBRT) is emerging as an alternative option to postpone starting ADT and its associated
side effects including the development of drug resistance. The aim of this study was to
determine progression free-survival (PFS) and treatment failure free-survival (TFFS) after
PSMA-PET/CT-based SBRT in OMPC patients. The efficacy and safety of single fraction
radiosurgery (SFRS) and ADT delay were investigated.
Methods
Patients with�5 metastases from OMPC, with/without ADT treated with PSMA-PET/CT-
based SBRT were retrospectively analyzed. PFS and TFFS were primary endpoints. Second-
ary endpoints were local control (LC), overall survival (OS) and ADT-free survival (ADTFS).
Results
Fifty patients with a total of 75 metastases detected by PSMA-PET/CT were analyzed. At
the time of SBRT, 70% of patients were castration-sensitive. Overall, 80% of metastases
were treated with SFRS (median dose 20 Gy, range: 16–25). After median follow-up of 34
months (range: 5–70) median PFS and TFFS were 12 months (range: 2–63) and 14 months
(range: 2–70), respectively. Thirty-two (64%) patients had repeat oligometastatic disease.
Twenty-four (48%) patients with progression underwent second SBRT course. Two-year LC
after SFRS was 96%. Grade 1 and 2 toxicity occurred in 3 (6%) and 1 (2%) patients,
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respectively. ADTFS and OS rates at 2-years were 60.5% and 100%, respectively. In multi-
variate analysis, TFFS significantly improved in patients with time to first metastasis (TTM)
>36 months (p = 0.01) and PSA before SBRT�1 ng/ml (p = 0.03).
Conclusion
For patients with OMPC, SBRT might be used as an alternative to ADT. This way, the start/
escalation of palliative ADT and its side effects can be deferred. Metastases treated with
PSMA-PET/CT-based SFRS reached excellent LC with minimal toxicity. Low PSA levels
and longer TTM predict elongated TFFS.
Introduction
For stage IV prostate cancer (PCA) palliative systemic therapy with androgen deprivation and/
or chemotherapy with docetaxel remains the standard of care [1]. However, some patients
with a limited number of metastases have a less aggressive disease course and might be treated
with metastasis directed therapy (MDT) for all tumor sites as an alternative to systemic treat-
ment [2]. These patients represent a condition known as oligometastatic disease, which is
defined as an intermediate state between localized cancer and widespread metastases [3]. In
the context of oligometastatic prostate cancer (OMPC), the desired effect of MDT is to post-
pone the start or escalation of androgen deprivation therapy (ADT) or in some cases even to
achieve long lasting remission [4]. As a result, delayed onset of ADT-associated side effects
and the inevitable emergence of therapy resistant PCA can be assumed.
The advent of positron emission tomography (PET) with different tracers has improved the
diagnosis of patients with OMPC by detecting early recurrence. The prostate-specific mem-
brane antigen (PSMA) is a membrane-specific type II glycoprotein that is overexpressed in
more than 80% of PCA cells and is therefore an ideal target for diagnostic imaging [5, 6].
Recently Gallium-68-labelled PSMA PET computed tomography (PSMA-PET/CT) was found
to be superior in localizing actively metabolizing tumor in patients with primary diagnosis or
recurrence of PCA compared to conventional imaging modalities and choline-based PET/CT
[7–11]. The detection rates for PSMA-PET/CT reported in the literature vary from 46% to
97% depending on the levels of prostate-specific antigen (PSA) [12–15]. Some authors
observed detection rates of>50% in patients with PSA <0.5 ng/mL [16, 17]. Such a high sensi-
tivity allows identification of very early recurrences with lesions <5 mm in size [10].
One-year local control (LC) rates reported after fractionated stereotactic body radiotherapy
(fSBRT) for patients with oligometastatic prostate cancer vary from 93–100%. Besides, no
grade�3 adverse events have been observed [18–20]. In this regard, single fraction radiosur-
gery (SFRS) is particularly attractive, since LC rates seem to be equally effective but treatment
is delivered in a single session [21].
The primary aim of this study was to assess progression-free survival (PFS) and treatment
failure free-survival (TFFS) after PSMA-PET/CT-based SFRS or fSBRT in patients with
OMPC with up to five metastases. Further endpoints included safety and efficacy of SFRS,
overall survival (OS) and possible delay of ADT initiation.
Materials and methods
Study population
In this retrospective analysis men with de-novo oligometastatic PCA (synchronous oligometa-
static disease or metachronous oligorecurrence or metachronous oligoprogression) who
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received curative 68Ga-PSMA-PET/CT-based SBRT for all metastases were included [22]. No
more than 5 metastases in�3 organs were allowed. The first metastasis was diagnosed after
median time of 37 months (1–199) from the initial diagnosis of PCA. All men had curative
therapy for prostate cancer. Both castration sensitive and castration resistant patients were eli-
gible for this study. The patients who started ADT and SBRT at the same time and patients
with previous SBRT were excluded.
This single center study was approved by the institutional medical ethics committee of the
Charité-Universitätsmedizin Berlin (EA1/214/16).
Radiotherapy
SBRT/SFRS was performed using mainly the CyberKnife (CK) Robotic Radiosurgery System
(Accurray1, USA) and dedicated stereotactic linear accelerator. CK Fiducial1 Tracking
(Accurray1, USA) was applied if indicated (e.g. lymph nodes expected to shift independently
to the bone) with one gold fiducial (1.0 mm x 5.0 mm) being placed within/close to the target
under CT guidance. Otherwise, patients were aligned to the spine using XsightSpine1 Track-
ing (Accuracy1, USA) or ExacTrac-based spine alignment (BrainLab1, Germany). A thin-
slice planning CT with 1.0–2.0 mm slices in supine position was obtained. PSMA-PET/CT
images were co-registered for contouring. The gross tumor volume was contoured on all axial
CT slices. The clinical target volume corresponded to the gross tumor volume. The planning
target volume was created by adding a 2–5 mm margin around the clinical target volume. A
SFRS/fSBRT dose was prescribed to the 70–80% isodose surrounding the planning target vol-
ume (Fig 1).
The fractionation regiments were selected taking into account the location of the lesion. If
the irradiated metastasis was in the immediate vicinity of the organs at risk and therefore dose
restrictions could not be met, fSBRT was indicated. Otherwise, SFRS was preferred over
fSBRT for patient comfort, economic and logistic advantages.
Follow-up
Follow-up was obtained every 3 months after SBRT within the first two years and half-yearly
thereafter. Adverse events were scored using the National Cancer Institute Common Toxic-
ity Criteria version 4. Additionally, patients attended routine follow-up visits at their
urologist.
Fig 1. PSMA-PET/CT based radiotherapy treatment plan of CyberKnife treatment system for bone metastasis located in the left ilium.
https://doi.org/10.1371/journal.pone.0240892.g001
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Endpoints
Endpoints of the study were PFS, TFFS, local control (LC), ADT-free survival (ADTFS), ADT-
escalation-free survival (ADTEFS) and OS calculated from the start of SBRT. PFS was defined
as freedom from biochemical failure, in-field progression, distant metastases or death. For
TFFS new tumor-directed therapy (e.g. repeated SBRT, start of ADT, escalation of an ongoing
ADT, surgery, chemotherapy) or death were determined as events. For LC, the in-field pro-
gression was counted as an event and was defined as an increase of metastasis volume or local
regrowth within the PTV. LC was assessed using conventional (CT or MRT) or functional
(PSMA-PET/CT) imaging. ADTFS was the interval until onset of ADT or death, whereas
ADTEFS was defined as time to ADT-escalation or death for patients with ongoing ADT. For
OS death of any cause was determined as an event.
Statistical analysis
Survival analysis was conducted using the Kaplan–Meier method. The Cox proportional haz-
ard model was used in univariate and multivariate analyses to calculate hazard ratios (HR)
with 95% confidence intervals (95% CI). Covariates with a p-value� 0.1 in univariate analysis
were included in the multivariate analysis. The Chi-square test was performed to compare var-
iables. A p-value of<0.05 was considered to be statistically significant. Data processing and
statistical analysis were conducted using FileMaker Pro 15 Advanced, Excel 2010 and IBM
SPSS Statistics 24 (SPSS Inc., Chicago, IL, USA).
Results
Between January 2012 and December 2016, 50 patients with OMPC and 75 oligometastases
detected by PSMA-PET/CT were treated with SBRT to all tracer-avid metastatic lesions.
Patients, metastases, and treatment characteristics are summarized in Table 1 and S1 Table. At
the initial diagnosis of PCA, 41 patients (82%) were classified as high risk according to the
D’Amico classification [23]. Three (6%) and 4 (8%) patients had low- and intermediate-risk
PCA, respectively. In 2 (4%) patients the risk class was unknown. Fifteen patients (30%) were
castration resistant. Median time from PCA diagnosis to the first metastasis (TTM) was 37
months (range: 1–199). Forty-eight (96%) patients had single organ involvement. The median
number of metastases treated per patient was one (range: 1–5). SFRS with a median PTV-sur-
rounding dose of 20 Gy (range: 16–25) was applied to 60 (80%) metastases, 13 (17.3%) received
fSBRT with 24 Gy in 3 fractions (3 x 8 Gy) and 2 other schedules (2.7%) (S2 Table).
With a median follow-up of 34 months (range: 5–70), the 1-, 2-years PFS and TFFS were
54%, 22%, and 55.2%, 23.4%, respectively (Fig 2A and 2B). Median PFS and TFFS were 12
months (95% CI: 7.6–16.3) and 14 months (95% CI: 10–17.9), respectively. The TFFS signifi-
cantly improved in patients with time to first metastasis >36 months (Fig 2C). Progression
occurred in 49 patients (98%), with 32 patients (64%) having repeat oligometastatic disease
with median two new metastases (range: 1–5). Forty-two (84%) patients underwent repeated
PSMA-PET/CT due to a rising PSA. Treatment failure was observed in 46 patients (92%). Of
these, 24 patients (48%) were treated with a second course of PSMA-PET/CT-based SBRT.
The median time from the first to the second course of SBRT was 17 months (95% CI: 9.7–
24.2). Fourteen patients (28%) started ADT, whereas in 6 patients (12%) ADT was escalated.
The pattern of progression and new tumor-directed therapies is presented in Table 2. At the
last follow-up, 31 (62%), 13 (26%), 3 (6%), and 1 (2%) patients had 2, 3, 4, and 5 courses of
SBRT, respectively.
Local control was available for 73 lesions. The 1-, 2-year LC rates after SFRS and fSBRT
were 98%, 96% and 100%, 100%, respectively (Fig 2D). There was no significant difference
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Table 1. Patients, tumor and treatment characteristics.
Characteristic Value
Age at PCA diagnosis, years
Median (range) 62 (47–75)
PSA at PCA diagnosis, ng/mL
Median (range) 9.8 (0.54–159)
PSA at SBRT, ng/mL
Median (range) 1.9 (0.16–59.8)













PCA treatment, N (%)
RP 15 (30)
RT 4 (8)
RP and RT 31 (62)
ADT at the time of SBRT, N (%)
no 35 (70)
yes 15 (30)
Time to metastases from diagnosis of PCA (months)
Median (range) 37 (1–199)






Primary site of metastases, N (%)





Bone and lymph node 2 (4)
Lung 1 (2)
Maximal SUV of PSMA-PET/CT
Median (range) 6 (2.6–42)
Fractionation schedules, N (%)
SFRS 60 (80)
3 fractions 13 (17.3)
(Continued)
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observed for LC in SFRS and fSBRT groups (p = 0.55). Two (2.7%) bone metastases relapsed
after SFRS with 20 Gy and 21 Gy, respectively. One was repeatedly treated with fSBRT.
At the last follow-up, 42.9% (15/35) of primarily ADT-naïve patients started treatment with
ADT. The 1- and 2-year rates for ADTFS were 76.4% and 60.5%, respectively. Median ADTFS
was not reached. ADT escalation was performed in 73.3% (11/15) of patients, with 1- and
2-year ADTEFS rates being 58.2% and 33.9%, respectively. The median ADTEFS was 27
months (95% CI: 8.8–45.1). Four patients were dead at the time of analysis. 1-, 2- and 5-years
OS rates were 100% and 100% and 80.3%. Median OS was not reached (Fig 2E). There was a
trend towards better OS in patients treated with the second course of SBRT compared to
patients receiving other therapy (Fig 2F).
Results of univariate and multivariate analysis of clinical prognostic factors affecting PFS
and TFFS are summarized in Table 3. In multivariate testing, a TTM>36 months (p = 0.01)
and PSA�1 ng/ml before SBRT predicted significantly longer TFFS (p = 0.03). In addition, a
longer PFS in univariate analysis was observed (p = 0.01) in patients with a TTM >36 months.
Multivariate analysis for PFS was not conducted because only one covariate had a p-value
�0.1.
Acute grade 1 toxicity was observed in three (6%) patients: 1 fatigue, 1 pain within the irra-
diated region, and 1 subacute pneumonitis. Only 1 (2%) grade 2 fatigue was observed. No
grade 3 or higher acute or any late toxicity occurred. No significant differences in terms of tox-
icities between SFRS and fSBRT were observed (p = .58).
Discussion
This study complements the existing literature on metastases-directed therapy (MDT) for
patients suffering from OMPC in several ways. First, we analyzed a large number of metastases
treated with PSMA-PET/CT based SFRS. Second, we reported outcomes after repeated use of
SBRT with the intention to defer the start or escalation of palliative ADT.
To the best of our knowledge, there are only two randomized studies that examined MDT
in comparison to observation for OMPC patients. In the STOMP Phase 2 trial, either SBRT
with 10 Gy in 3 fractions or surgery was used after staging with choline PET/CT [2]. Lately
announced 5-year follow-up results showed significantly lower rates of ADT onset in patients
after MDT (34% vs 8%, p = 0.06). The most recent ORIOLE phase 2 trial investigated the pro-
gression rate at 6 months after SBRT for up to 3 metastases [24]. Although PSMA-PET/CT
was performed at baseline, it was blinded to the radiation oncologist so that in some patients
not all PSMA-avid lesions were treated. The intervention arm showed a significantly reduced
progression rate of 19% vs 61% (p = 0.005). Furthermore, patients with no additional PSMA-




Median dose (Gy) for SFRS (range) 20 (16–25)
Median dose (Gy) for fSBRT(range) 24 (19.2–28.8)
Abbreviations: ADT = androgen deprivation therapy; fSBRT = fractionated stereotactic body radiotherapy;
PCA = prostate cancer; PSA = prostate-specific antigen; PSMA-PET/CT = prostate-specific membrane antigen
positron emission tomography/computed tomography; RP = radical prostatectomy; RT = radiotherapy;
SBRT = stereotactic body radiotherapy; SFRS = single fraction radiosurgery; SUV = standardized uptake value.
https://doi.org/10.1371/journal.pone.0240892.t001
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Fig 2. Kaplan–Meier survival curves for: (A) progression-free survival (PFS), (B) treatment failure-free survival (TFFS) (C) treatment failure-free survival by time from
PCA diagnosis to first metastasis:>36 months vs�36 months, (D) local control (LC) by fractionation schedules: single fraction radiosurgery (SFRS) vs fractionated
stereotactic body radiotherapy (fSBRT), (E) overall survival (OS), (F) overall survival by therapy initiated after progression: repeated SBRT (re-SBRT) vs other.
https://doi.org/10.1371/journal.pone.0240892.g002
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p = 0.0008), suggesting that PSMA-PET/CT-based SBRT may not only serve to treat existing
metastases, but may also modulate course of disease.
In our analysis, the majority of patients (64%) with a progression after SBRT developed up
to five new metastases and were therefore still considered to have a repeat OMPC. Other
authors reported similar results, with 70–75% of patients treated with SBRT remaining oligo-
progressive or oligorecurrent after distant relapse with median�3 metastases [25, 26]. This
implies that in case of progression most patients are still eligible for further MDT.
Median PFS reported in the literature varies from 3 to 24 months (Table 4). Some authors
observed a 21-month difference in median PFS in castration-sensitive versus castration-resis-
tant patients with a maximum 3 bone metastases [20]. Furthermore, another small series
found 1-year PFS rates to be 67% vs 0% in castration-sensitive compared to castration-resistant
patients after radiotherapy to a maximum 3 metastases [18]. Such a difference in PFS between
the groups raises the question of whether patients with progression despite hormone therapy
are suitable candidates for MDT alone. However, in some castration-resistant patients, pro-
gression is limited only to a few sites, while the remaining disease is controlled by systemic
therapy. In this case, the eradication of castration-resistant metastases using MDT allows a
continuation of ongoing ADT and thus spares a second-line hormone or chemotherapy for
further progression [27]. In contrast to the aforementioned studies, Valeriani and colleagues
observed a relatively high median PFS of 18.4 months in 29 castration-resistant patients with
oligoprogressive PCA treated with local radiotherapy for up to 3 metastases [28]. In present
study, no differences in PFS in patients with or without ADT at the time of SBRT was
observed.
In the case of repeat OMPC, multiple SBRT might be used as a bridging treatment to delay
palliative system therapy. Recently, prospective analysis of 199 OMPC patients (76.4% staged
Table 2. Progression pattern and therapy initiated in case of treatment failure in all patients.
Progression pattern Number (%) Therapy in case of TF Number (%)
Repeat OMPC (5�metastases) 32 (64)
SBRT 22 (68.8)
ADT initiation 7 (21.9)
ADT escalation 1 (3.1)
combined 1 (3.1)
no 1 (3.1)
Polymetastatic disease (5 > metastases) 6 (12)
ADT initiation 4 (66.7)
ADT escalation 2 (33.3)
Biochemical (PSA) progression 6 (12)
ADT initiation 3 (50)
ADT escalation 3 (50)
In-field progression 2 (4)
SBRT 1 (50)
Surgery 1 (50)
Prostate/prostatic lodge recurrence 3 (6)
SBRT 1 (33.3)
no 2 (66.7)
No progression 1 (2) no 1 (100)
Abbreviations: ADT = androgen deprivation therapy; OMPC = oligometastatic prostate cancer; PSA = prostate-specific antigen; SBRT = stereotactic body radiotherapy;
TF = treatment failure.
https://doi.org/10.1371/journal.pone.0240892.t002
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with PSMA-PET/CT) with�5 metastases after SBRT reported 31.7%, 9.5% and 4% of patients
receiving second, third, and fourth courses of SBRT [29]. After a median follow-up of 35.1
months, the majority of patients (51.7%) did not require a further tumor directed therapy. In
49.3% of patients palliative systemic- or radiotherapy had been postponed for a median time
of 27.1 months (95% CI 21.8–29.4). Bouman–Wammes et al. investigated the impact of SBRT
Table 3. Univariate and multivariate analysis of factors influencing PFS and TFFS.
PFS TFFS
Univariable Univariable Multivariable
Determinant HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Time from PCA to first metastasis (months)
> 36 1 1 1
� 36 2.17 (1.20–3.91) 0.01 2.18 (1.18–4.02) 0.01 2.54 (1.33–4.82) 0.01
Gleason score
�7 1 1 N.A.
>7 1.20 (0.66–2.17) 0.55 0.99 (0.73–1.33) 0.96
Primary tumor size
T� 2 1 1 N.A.
T > 2 0.98 (0.53–1.79) 0.95 0.99 (0.53–1.84) 0.99
Regional lymph node involvement at PCA diagnosis
N0 1 1 N.A.
N1 1.50 (0.75–3.00) 0.25 1.66 (0.83–3.32) 0.15
Initial PSA (ng/ml)
� 10 1 1 N.A.
> 10 0.89 (0.47–1.60) 0.65 0.91 (0.49–1.67) 0.75
PSA (ng/ml) before SBRT
� 1 1 1 1
> 1 1.69 (0.88–3.22) 0.11 1.02 (0.99–1.05) 0.06 2.25 (1.10–4.59) 0.03
Salvage radiotherapy after prostatectomy
Yes 1 1 N.A.
No 1.27 (0.71–2.27) 0.43 1.27 (0.70–2.31) 0.43
Concomitant ADT
Yes 1 1 N.A.
No 1.57 (0.84–2.93) 0.16 1.69 (0.88–3.25) 0.11
Number of metastases at SBRT
1 1 1 1
>1 1.54 (0.84–2.83) 0.16 1.70 (0.91–3.17) 0.10 1.42 (0.73–2.73) 0.30
Number of affected organs
1 1 1 N.A.
>1 1.53 (0.54–4.34) 0.42 1.72 (0.61–4.90) 0.31
Bone metastases
No 1 1 N.A.
Yes 0.81 (0.46–1.42) 0.46 0.84 (0.47–1.51) 0.56
Extra-pelvic lymph node metastases
No 1 1 N.A.
Yes 0.75 (0.32–1.73) 0.50 0.62 (0.27–1.48) 0.29
Abbreviations: CI = confidence interval; HR = hazard ratio; NA = not assessed; PCA = prostate cancer; PFS = progression free-survival; PSA = prostate-specific antigen;
SBRT = stereotactic body radiotherapy; TFFS = treatment failure-free survival.
https://doi.org/10.1371/journal.pone.0240892.t003
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Table 4. Studies on SBRT for OMPC patients.













2020 54/72 �3 LN = 33% 100% SBRT with 19.5 to 48.0 Gy in 1
to 3 fractions
Median in SBRT arm
was not reached after





Siva et al. [21] 2018 33/50 �3 LN = 36.4% 67% SFRS with 20 Gy 1-yr: 58% 2-yr: 48%




2017 62/116 �3 LN = 54.8% 100% SBRT in 80.6% Median 10 months in
MDT arm vs 6 months
in surveillance arm
Median 21 months in







2020 176/353 �5 LN = 34.7% Unknown SBRT in 73% with median 27
Gy in median 3 fractions;
Conventional RT in 27% with
median 60 Gy
Median 39.3 months N.A.
Bone = 42.6%
Both = 22.7% 2-yr: 63.1%,
Nicosia et al.
[32]
2020 109/155 �5 LN = 100% 100% SBRT with median 36 Gy in
4–7 fractions





2020 78/185 �5 LN = 68.2% Unknown SBRT in 20.5% Median: 17.0 months Median not reached after
16 months of follow-upBone = 45%
Visceral = 6.5% 1-yr: 55.3%,
Franzese et al.
[34]
2019 92/119 �5 LN, bone and
visceral
66% SBRT with median 42 Gy in 2
to 8 fractions
Median 9.4 months N.A.
1-yr: 42.8%
3-yr: 16.7%,
Patel et al. [20] 2019 51/64 �3 Bone = 100% 82% SBRT with 24 to 30 Gy in 3 or
5 fractions
Median 24 months in






2019 29/37 �3 LN = 5.4% 0% SBRT for 16.2% Median 18,4 months N.A.
Bones = 83.8%
Other = 10.8% 2-yr: 38.3%
3-yr: 8.5%,
Ong et al. [19] 2019 20/26 �3 LN = 75% 100% SBRT with 30 Gy in 3 fractions
and 35 to 40 Gy in 5 fractions
1-yr: 62% 1-yr: 70%
Bone = 15%
Both = 10%




2017 141/209 �3 LN = 79% 71% SBRT with 24 to 45 Gy in 3 to
6 fractions
Median in castration
sensitive 17.7 months vs











2017 43/54 �4 LN = 76.6% 100% SBRT with 30 or 35 Gy in 3 or
5 fractions





2016 29/45 �3 LN = 55.5% 62% SBRT with 24 Gy or 27 Gy in 1
or 3 fractions
N.A. Median (systemic therapy
free survival) 39.7 monthsBone = 44.5%
(Continued)
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on delaying ADT for 43 hormone-sensitive PCA patients with<5 metastases detected using
choline-PET-CT [30]. The second SBRT course was applied in 16.3% of patients with a
median 19.8 months between the courses, which is in line with our results. The median
ADTFS observed within this group was 32.1 months (95% CI: 7.8–56.5). Furthermore, Trig-
giani and colleagues observed a 18% rate of repeated SBRT in 141 patients with hormone-
sensitive and castration-resistant OMPC treated with SBRT for up to 3 metastases [35]. In
our cohort, a second SBRT course was the treatment of choice in almost 50% of patients
with progression and thus ADT initiation or escalation was delayed. The median ADTFS
was not reached after 34 months follow-up. Furthermore, we observed a trend (p = 0.055)
toward better OS after second SBRT course compared to other therapy initiated after
progression.
The median ADTFS reported in the literature for patients with OMPC after MDT varies
between 20.9 and 39.7 months, which is comparable to our results Table 4. However, the
results of different studies should be compared with caution, due to diverse inclusion criteria
(e.g. number of metastases), staging methods (PSMA/PET-CT, FDG/PET-CT), treatment
modalities (SBRT, surgery) and different indications for ADT start used.
In our analysis SFRS showed excellent LC rates of 96% at 2 years with no grade�3 adverse
events. Siva et al. prospectively analyzed safety and feasibility of SFRS with 20 Gy for bone and
lymph node metastases staged with sodium fluoride PET/CT. After treating 50 lesions in 33
patients, the authors observed 1- and 2-year LC rates of 97% and 93%, respectively. Grade 3
adverse events were observed in one patient (3%) [21]. Muldermans et al. reported LC at 2
years of 82% after treating 69 patients with 81 metastases– 88% received SFRS with a median
dose of 16 Gy (range: 16–24) [37]. Seventy percent of patients were staged with choline PET/
CT. In multivariate analysis, radiation dose�18 Gy was associated with better LC. No grade
�2 adverse events were observed. Although, the prescribed dose varied within the studies
emerging data including our study show that SFRS can be safely used in favor of patients’ con-
venience and provide excellent LC rates.
In our analysis a TTM of more than 36 months was found to be an independent prognostic
factor for prolonged TFFS and was associated with greater PFS. Benefits might be explained by
an indolent tumor biology with a lower metastatic potential. Supporting this hypothesis, analy-
sis of a multi-institutional study on oligometastatic disease from several tumor entities showed
that longer TTM using the MDT-approach resulted in improved survival [38].
Table 4. (Continued)












2014 50/70 �3 LN = 54% 100% SBRT with 30 or 50 Gy in 3 or
10 fractions
Median 19 months Median 25 months
1-yr: 82%Bone = 44%
Visceral = 2% 1-yr: 64% 2-yr: 60%
2-yr: 35%,
Current study 2020 50/75 �5 LN = 48% 70% SFRS 80% with median 20 Gy Median 12 months Median not reached
Bone = 46%
Both = 4% 1-yr: 54% 1-yr: 76%
Visceral = 2% 2-yr: 22% 2-yr: 60%
Abbreviations: ADTFS = androgen deprivation therapy-free survival; LN = lymph node; MDT = metastasis directed therapy; N.A. = not assessed;
OMPC = oligometastatic prostate cancer; RT = radiotherapy; SBRT = stereotactic body radiotherapy; SFRS = single fraction radiosurgery.
https://doi.org/10.1371/journal.pone.0240892.t004
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The retrospective study design, relatively small sample size including heterogeneous
patients, inherent patient selection bias and lack of control group are the major limitations of
our study. Furthermore, the comparison between SFRS and fSBRT group needs to be inter-
preted with caution due to limited number of metastases treated with fSBRT. The majority of
patients had a high risk PCA, so conclusions for patients with low and medium risk of PCA
should be drawn carefully. Nonetheless, we were able to show the efficacy, safety, and excellent
local control rates after SFRS use in OMPC patients.
Conclusions
In conclusion, our study suggests that PSMA-PET/CT-based SFRS might be considered a valid
treatment option for OMPC patients, including cases with repeat oligometastatic disease. This
way, the onset or escalation of palliative ADT and its potential side effects can be avoided.
Metastases treated with SFRS reached excellent local control rates with minimal toxicity. Low
PSA levels and longer TTM predicts elongated TFFS. Randomized studies are needed to sup-
port our findings.
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